THURSDAY, Oct. 11, 2018 (HealthDay News) — More than half of patients who are dually eligible for Medicare and Medicaid and are designated as high-cost in one year remain persistently high-cost over three years, according to a study published online Oct. 2 in the Annals of Internal Medicine.
Jose F. Figueroa, M.D., M.P.H., from Harvard University in Boston, and colleagues used data from the Medicare-Medicaid Linked Enrollee Analytic Data Source (2008 to 2010) to identify 1,928,340 dual-eligible Medicare and Medicaid beneficiaries who were alive all three years. High-cost beneficiaries were defined as having spending in any given year in the top 10 percent for that year.
The researchers found 192,835 high-cost patients in the first year, more than half (54.8 percent) of whom remained high-cost across all three years. Persistently high-cost patients were younger, had fewer medical comorbidities, and had greater intellectual impairment than transiently high-cost patients. Costs per year were $161,224 for persistently high-cost patients compared with $86,333 for transiently high-cost patients and $22,352 for non-high-cost patients. Persistently high-cost patients’ spending was mostly related to long-term care (68.8 percent), with very little (<1 percent) related to potentially preventable hospitalizations for ambulatory care-sensitive conditions.
“Strategies to control costs in dual-eligible beneficiaries may be more effective if they focus on reducing spending in long-term care rather than on reducing potentially preventable hospitalizations,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Copyright © 2018 HealthDay. All rights reserved.
